 Aravive Inc NASDAQ: ARAV has announced new data from the Phase 1b portion of the ongoing Phase 1b2 trial of batiraxcept in clear cell renal cell cancer ccRCC. 26 previously treated ccRCC patients have been treated with batiraxcept at doses of 15 mgkg n16 and 20 mgkg n10. 